Current Prostate Cancer Treatments: Effect on Quality of Life

Urology

Volumn 73, Issue 5 SUPPL., 2009, Pages

  Gomella, Leonard G ^a   Johannes, James ^a   Trabulsi, Edouard J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SCREENING; CAREGIVER; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CRYOTHERAPY; DEPRESSION; DISEASE SEVERITY; ERECTILE DYSFUNCTION; FATIGUE; FRACTURE; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEALTH CARE COST; HIGH INTENSITY FOCUSED ULTRASOUND; HOT FLUSH; HUMAN; LIBIDO; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RISK REDUCTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEAKNESS; WEIGHT GAIN;

COMBINED MODALITY THERAPY; COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; MALE; PROSTATIC NEOPLASMS; QUALITY OF LIFE;

EID: 64349114265     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2009.03.003     Document Type: Article

References (60)

1. Garcia M., Jemal A., Ward E., et al. Global cancer facts and figures 2007 (2007). http://www.cancer.org/downloads/STT/Global_Cancer_Facts_and_Figures_2007_rev.pdf Accessed May 23, 2008
2. Ries L., Melbert D., Drapcho M., et al. SEER cancer statistics review (based on November 2007 SEER data submission, posted to the SEER Web site, 2008). http://seer.cancer.gov/csr/1975_2005/ Accessed May 30, 2008
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
4. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177 (2007) 2106-2131
5. Mohler J., Bahnson R., Boston B., et al. NCCN Clinical Practice Guidelines in Oncology Prostate cancer (February 21, 2008). http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf Accessed May 23, 2008
6. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
7. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352 (2005) 1977-1984
8. Shelley M.D., Kumar S., Wilt T., et al. A systematic review and metal-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev 35 (2008) 9-17
9. Gomella L.G. Addressing the needs of the high-risk prostate cancer patient. Rev Urol 7 suppl 5 (2005) S18-S28
10. Mulhall J.P. Penile rehabilitation following radical prostatectomy. Curr Opin Urol 18 (2008) 613-620
11. Hu J.C., Wang Q., Pashos C.L., et al. Utilization and outcomes of minimally invasive radical prostatectomy. J Clin Oncol 26 (2008) 2278-2284
12. Blute M.L. Radical prostatectomy by open or laparoscopic/robotic techniques: an issue of surgical device or surgical expertise?. J Clin Oncol 26 (2008) 2248-2249
13. Jani A.B., Su A., Correa D., et al. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Prostate Cancer Prostatic Dis 10 (2007) 82-86
14. Kumar R.J., Barqawi A., and Crawford E.D. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 7 suppl 5 (2005) S37-S43
15. Green H.J., Pakenham K.I., Headley B.C., et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 90 (2002) 427-432
16. Rosenblatt D.E., and Mellow A. Depression during hormonal treatment of prostate cancer. J Am Board Fam Pract 8 (1995) 317-320
17. Sharpley C.F., and Christie D.R. An analysis of the psychometric profile and frequency of anxiety and depression in Australian men with prostate cancer. Psycho-oncol 16 (2007) 660-667
18. Gomella L.G. Contemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues. BJU Int 99 suppl 1 (2007) 25-29
19. Sharifi N., Gulley J.L., and Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 294 (2005) 238-244
20. Greenspan S.L., Nelson J.B., Trump D.L., et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 26 (2008) 4426-4434
21. Israeli R.S., Ryan C.W., and Jung L.L. Managing bone loss in men with locally advanced prostate cancer receiving androgen deprivation therapy. J Urol 179 (2008) 414-423
22. Kiratli B.J., Srinivas S., Perkash I., et al. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology 57 (2001) 127-132
23. Thorpe J.F., Jain S., Marczylo T.H., et al. A review of phase III clinical trials of prostate cancer chemoprevention. Ann R Coll Surg Engl 89 (2007) 207-211
24. Simoneau A.R. Treatment- and disease-related complications of prostate cancer. Rev Urol 8 suppl 2 (2006) S56-S67
25. Wu A.K., Cooperberg M.R., Sadetsky N., et al. Health related quality of life in patients treated with multimodal therapy for prostate cancer. J Urol 180 (2008) 2415-2422
26. Chen R.C., Clark J.A., Manola J., et al., JA. Treatment "mismatch" in early prostate cancer: do treatment choices take patient quality of life into account?. Cancer 112 (2008) 61-68
27. Clark J.A., and Talcott J.A. Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made. J Clin Oncol 24 (2006) 4457-4463
28. Carlsson S., Aus G., Wessman C., et al. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA)-results from a prospective, population-based, randomised study. Eur J Cancer 43 (2007) 2109-2116
29. Taupin D., Chambers S.L., Corbett M., et al. Colonoscopic screening for colorectal cancer improves quality of life measures: a population-based screening study. Health Qual Life Outcomes 4 (2006) 82-87
30. Arcangeli C.G., Ornstein D.K., Keetch D.W., et al. Prostate-specific antigen as a screening test for prostate cancer: the United States experience. Urol Clin North Am 24 (1997) 299-306
31. Katz D.A., Jarrard D.F., McHorney C.A., et al. Health perceptions in patients who undergo screening and workup for prostate cancer. Urology 69 (2007) 215-220
32. Love A.W., Scealy M., Bloch S., et al. Psychosocial adjustment in newly diagnosed prostate cancer. Aust N Z J Psychiatry 42 (2008) 423-429
33. Rosenfeld B., Roth A.J., Gandhi S., et al. Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psycho-oncol 13 (2004) 800-807
34. Awsare N.S., Green J.S., Aldwinckle B., et al. The measurement of psychological distress in men being investigated for the presence of prostate cancer. Prostate Cancer Prostatic Dis 11 (2008) 384-389
35. Katz A., and Katz A. The top 13: what family physicians should know about prostate cancer. Can Fam Physician 54 (2008) 198-203
36. Bellizzi K.M., Latini D.M., Cowan J.E., et al. Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer. Urology 72 (2008) 1269-1273
37. Arredondo S.A., Downs T.M., Lubeck D.P., et al. Watchful waiting and health related quality of life for patients with localized prostate cancer: data from CaPSURE. J Urol 179 suppl (2008) S14-S18
38. National Cancer Institute. Observation or radical treatment in patients with prostate cancer. http://clinicaltrials.gov/ct2/show/NCT00499174 Accessed December 20, 2008
39. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
40. Burnett A.L., Aus G., Canby-Hagino E.D., et al. Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol 178 (2007) 597-601
41. Hinz A, Krauss O, Stolzenburg JU, et al. Anxiety and depression in patients with prostate cancer and other urogenital cancer: a longitudinal study. Urol Oncol. Epub 2008 April 25.
42. Bacon C.G., Giovannucci E., Testa M., et al. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer 94 (2002) 862-871
43. Eller L.S., Lev E.L., Gejerman G., et al. Prospective study of quality of life of patients receiving treatment for prostate cancer. Nurs Rev 55 suppl (2006) S28-S36
44. Fletcher B.S., Paul S.M., Dodd M.J., et al. Prevalence, severity, and impact of symptoms on female family caregivers of patients at the initiation of radiation therapy for prostate cancer. J Clin Oncol 26 (2008) 599-605
45. National Cancer Institute. Cancer trends progress report-2007 update (2007). http://progressreport.cancer.gov Accessed December 20, 2008
46. Warren J.L., Yabroff K.R., Meekins A., et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 100 (2008) 888-897
47. Wilson L.S., Tesoro R., Elkin E.P., et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 109 (2007) 518-527
48. Fireman B.H., Quesenberry C.P., Somkin C.P., et al. Cost of care for cancer in a health maintenance organization. Health Care Financ Rev 18 (1997) 51-76
49. Riley G.F., Potosky A.L., Lubitz J.D., et al. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 33 (1995) 828-841
50. Yabroff K.R., Warren J.L., and Brown M.L. Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol 4 (2007) 643-656
51. Lippman S.M., Klein E.A., Goodman P.J., et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301 (2008) 39-51
52. Avodart® (dutasteride) prescribing information (2008), GlaxoSmithKline, Research Triangle Park, NC
53. Proscar® (finasteride) prescribing information (2007), Merck & Company, Whitehouse Station, NJ
54. Thompson I.M., Goodman P.J., Tangen C.M., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215-224
55. Andriole G.L., Roehrborn C., Schulman C., et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 64 (2004) 537-541
56. Andriole G., Bruchovsky N., Chung L.W., et al. Dihydrotestosterone and the prostate: the scientific rationale for 5α-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 172 4 Pt. 1 (2004) 1399-1403
57. Roehrborn C.G., Boyle P., Nickel J.C., et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60 (2002) 434-441
58. McConnell J.D., Bruskewitz R., Walsh P., et al., Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338 (1998) 557-563
59. Kramer B.S., Hagerty K.L., Justman S., et al. Use of 5-α-Reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 clinical practice guideline. J Clin Oncol 27 (2009) 1502-1516
60. Svatek R.S., Lee J.J., Roehrborn C.G., et al. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 112 (2008) 1058-1065